References
- Dixon M F, Sobala G M. Gastritis and duodenitis: histopathological spectrum. Eur J Gastroenterol Hepatol 4 Suppl 1992; 2: 17–23
- Hentschell E, Brantstätter G, Dragosics B, Hirschl A, Nemec H, Schutze K. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308–312
- Passonet J, Freidman G D, Vandersteed D P. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127–1131
- Hansson L E, Engstrand L, Nyren O, Evans D J, Jr., Lindgren A, Bergström R. Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma. Gastroenterology 1993; 105: 1098–1103
- Hansson L E, Engstrand L, Nyren O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology 1995; 109: 885–888
- Logan R PH. The 13C-UBT for the detection of Helicobacter pylori. Helicobacter pylori and gastroduodenal disease, B J Rathbone, R V Heatley. Blackwell Scientific Publications, London 1992; 88–107
- Kosunen T, Seppälä K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893–895
- Fendrick A M, Chernew M E, Hirth R A, Bloom B S. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995; 123: 260–268
- Jones D M, Eldridge J, Fox A, Sethi P, Whorwell P J. Antibody to the gastric campylobacter-like organism (“Campylobacter pyloris'') – clinical correlations and distribution in the normal population. J Med Microbiol 1986; 22: 57–62
- Veenendaal R A, Pena A S, Meijer J L. Long-term surveillance after treatment of Helicobacter pylori infection. Gut 1991; 32: 1291–1294
- Cutler A, Schubert A, Schubert T. Role of Helicobacter pylori serology in evaluating treatment success. Dig Dis Sciences 1993; 38: 2262–2266
- Lelwala-Guruge J, Nilsson I, Ljungh A, Wadstrom T. Cell surface proteins of Helicobacter pylori as antigens in an EIA and a comparison with three commercial EIA. Scand J Infect Dis 1992; 24: 457–465
- Megraud F, Rabbe M P, Denis F. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989; 27: 1870–1873
- Thijs J, Zwet A, Meyer B, Berrelkamp R. Serology to monitor the efficacy of anti-Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1994; 6: 579–583
- Wang W-M, Chen C-Y, Jan C-M, Chen L-T, Perng D-S, Lin S-R, Liu C-S. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol 1994; 89: 1793–1796
- Hirschl A, Brandstätter G, Dragosics B, Hentschel E, Kundi M, Rotter M, Schutze K, Taufer M. Kinetics of specific antibodies for monitoring the effect of anti-Helicobacter pylori chemotherapy. J Infect Dis 1993; 168: 763–766
- Cutler A, Prasad M. Long-term follow up of Helicobacter pylori serology after successful eradication. Am J Gastroenterol 1996; 91: 85–88
- Befrits R, Granström M, Rylander M, Rubio C. Helicobacter pylori in 205 consecutive patients. Scand J Infect Dis 1993; 25: 185–191
- Crabtree J E, Wyatt J I, Sobala G M, Millar G, Tompkins D S, Primrose J N. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut 1993; 34: 1339–1343